MedPath

Study of Sc-FOS for Pouchitis Prevention

Phase 1
Completed
Conditions
Pouchitis
Interventions
Drug: Short-Chain Fructooligosaccharide
Registration Number
NCT02203955
Lead Sponsor
Mayo Clinic
Brief Summary

The main objective is to compare prebiotic therapy with placebo for the prevention of pouchitis after closure of diverting ileostomy in patients with an ileal pouch anal anastomosis. This study will also characterize the effects of prebiotics on the fecal microbiota and fecal microbial metabolites and correlate these effects with the primary outcome of development of pouchitis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13
Inclusion Criteria

Not provided

Exclusion Criteria
  1. Crohn's disease.
  2. Perianal disease (including abscess, fissure, or stricture)
  3. Pregnancy
  4. Lactation
  5. Concurrent treatment for IBD or pouchitis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Short-Chain FructooligosaccharideShort-Chain Fructooligosaccharide4 chews (8.0 g scFOS) orally per day for 12 months
MaltodextrinMaltodextrin4 chews (maltodextrin) daily for 12 months
Primary Outcome Measures
NameTimeMethod
Mean Change in Pouchitis Disease Activity Index (PDAI) at One Yearbaseline, 1 year

In the PDAI, an overall score is calculated from three separate six-point scales comprising of clinical symptoms, endoscopic findings and histological changes. The PDAI incorporates histological features of acute inflammation, and establishes a cut-off of seven for differentiation between 'pouchitis (≥7 points) and 'no pouchitis' (\<7 points).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Mayo Clinic in Rochester

🇺🇸

Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath